For the Inventor, By the Inventor

Enter assignee name

Stockholm, Sweden

Vicore Pharma Ab

USPTO Granted Patents = 18

% Expired Patents = 27.8

EPO Patents = 8

Trademarks = 4

Forward Citations = 20

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Anders Rudolf Hallberg (7 out of 9 patents)

Mathias Alterman (5 out of 8 patents)

Carl-Johan Dalsgaard (4 out of 6 patents)

4. Rohit Batta (4 out of 4 patents)

5. Ola Camber (4 out of 4 patents)

6. Bengt Ohlsson (3 out of 6 patents)

7. Tomas Fex (3 out of 4 patents)

8. Xiongyu Wu (2 out of 2 patents)

9. Mats Larhed (2 out of 5 patents)

10. Johan Raud (1 out of 3 patents)

11. Ulrike Steckelings (1 out of 1 patent)

12. Thomas Unger (1 out of 1 patent)

13. Murugaiah Andappan Murugaiah Subbaiah (1 out of 1 patent)

14. Christina Johansson (1 out of 1 patent)

15. Stefan Grudén (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. 12715864 - Process for the synthesis of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (2026-08-25),

2. 12708615 - SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS (2026-08-18),

3. 12605341 - Dry powder composition for peroral administration (2026-04-21),

4. 12441718 - Selective angiotensin II compounds (2025-10-14),

5. 12435072 - Compounds (2025-10-07),

6. 12213961 - Treatment of idiopathic pulmonary fibrosis (2025-02-04),

7. 12128029 - Treatment of idiopathic pulmonary fibrosis (2024-10-29),

8. 12121614 - Delayed release composition for peroral administration (2024-10-22),

9. 11844868 - Dry powder composition for peroral administration (2023-12-19),

10. 11819494 - Treatment of idiopathic pulmonary fibrosis (2023-11-21),

11. 11654115 - Delayed release composition for peroral administration (2023-05-23),

12. 11123329 - Use of angiotensin II type 2 receptor agonist (2021-09-21),

13. 8835471 - Use of angiotensin II agonists (2014-09-16),

14. 8357710 - Bicyclic angiotensin II agonists (2013-01-22),

15. 8124638 - Tricyclic compounds useful as angiotensin II agonists (2012-02-28),

Vicore Pharma Ab is a biopharmaceutical company focused on developing innovative treatments for severe lung diseases. Their lead product candidate, C21, targets fibrotic lung diseases and has shown promising results in clinical trials. Vicore Pharma aims to improve the lives of patients with unmet medical needs through their cutting-edge research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

18 Patents

#52 in Stockholm

#365 in Sweden

#34,099 in the World

Stockholm, Sweden

Vicore Pharma Ab

Forward Citations = 20

21 inventors:

Anders Rudolf Hallberg (7 out of 9 patents)

Mathias Alterman (5 out of 8 patents)

Carl-Johan Dalsgaard (4 out of 6 patents)

4. Rohit Batta (4 out of 4 patents)

5. Ola Camber (4 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…